Ascendis Pharma A/S $ASND Stake Lowered by Jump Financial LLC

Key Points

• Jump Financial LLC significantly reduced its stake in Ascendis Pharma A/S by selling 10,644 shares, bringing its total holdings down to 1,461 shares valued at $228,000.
• HighTower Advisors LLC substantially increased its position in Ascendis Pharma A/S by 413.1%, now holding 18,032 shares worth $2,810,000.
• Ascendis Pharma A/S reported better-than-expected earnings, with an EPS of ($0.93) compared to analysts' estimates of ($1.42), and revenue of $216.28 million versus expectations of $163.17 million.

Jump Financial LLC lowered its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 87.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,461 shares of the biotechnology company's stock after selling 10,644 shares during the quarter. Jump Financial LLC's holdings in Ascendis Pharma A/S were worth $228,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its stake in shares of Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $2,123,000. Janus Henderson Group PLC lifted its stake in shares of Ascendis Pharma A/S by 4.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after purchasing an additional 193,688 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $28,000. Finally, Tema Etfs LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $2,621,000.

Wall Street Analyst Weigh In

A number of brokerages have commented on ASND. Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Royal Bank Of Canada boosted their price objective on Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Morgan Stanley began coverage on Ascendis Pharma A/S in a research note on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective on the stock. Bank of America boosted their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $295.00 price target (up previously from $289.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Fifteen research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of "Buy" and an average target price of $244.36.

Ascendis Pharma A/S Trading Down 1.0%

NASDAQ ASND traded down $1.96 on Tuesday, hitting $203.27. 37,056 shares of the stock traded hands, compared to its average volume of 488,271. The stock has a 50-day moving average of $183.33 and a 200 day moving average of $168.42. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $208.16. The company has a market capitalization of $12.44 billion, a P/E ratio of -39.41 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. As a group, equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.